Follow The Filings

IMVT Immunovant

Immunovant earnings company data as of 11:46 AM ET 11/17

  • 1 of 1 EPS beats

History

1 period, newest first. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2027 Q2 9 Nov EPS -0.72 -0.47 Beat
Rev — — —

Insider trades

Open-market buys and sales by IMVT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All IMVT insider trades
  • $350M bought by 1 insider
  • $10.7M sold by 5 insiders outside a trading plan
  • $601K sold by 2 insiders under 10b5-1 plans
  1. Atul Pande Director
    Planned sale
    $108K 3,000 shares at $36.00 2.5% of stake
    Traded Nov 11 Filed Nov 12
  2. Atul Pande Director
    Planned sale
    $65K 1,500 shares at $43.27 1.3% of stake
    Traded Aug 28 Filed Aug 28
  3. Atul Pande Director
    Planned sale
    $60K 1,500 shares at $39.80 1.3% of stake
    Traded Jul 24 Filed Jul 24
  4. Melanie Gloria COO
    Sale
    $679K 17,714 shares at $38.31 7.3% of stake
    Traded Jun 26 Filed Jun 26
  5. Jay S. Stout Chief Technology Officer
    Sale
    $1.5M 40,000 shares at $38.31 16% of stake
    Traded Jun 26 Filed Jun 26
  6. Christopher Van Tuyl Chief Legal Officer
    Sale
    $683K 17,824 shares at $38.31 9% of stake
    Traded Jun 26 Filed Jun 26
  7. Tiago Girao CFO
    Sale
    $385K 10,000 shares at $38.46 3.9% of stake
    Traded Jun 26 Filed Jun 26
  8. Atul Pande Director
    Planned sale
    $57K 1,500 shares at $38.01 1.3% of stake
    Traded Jun 26 Filed Jun 26
  9. Atul Pande Director
    Planned sale
    $51K 1,500 shares at $34.02 1.3% of stake
    Traded Jun 15 Filed Jun 16
  10. Andrew J. Fromkin Director
    Sale
    $7.4M 221,951 shares at $33.51 75% of stake
    Traded May 28 Filed May 29
  11. Atul Pande Director
    Planned sale
    $192K 6,000 shares at $32.00 4.9% of stake
    Traded May 20 Filed May 20
  12. Robert Graham Susman Director
    Planned sale
    $68K 2,502 shares at $27.17 6.4% of stake
    Traded May 1 Filed May 1
  13. Roivant Sciences Ltd. Director
    Buy
    $350M 16.7M shares at $21.00 +17% to stake
    Traded Dec 12, 2025 Filed Dec 12, 2025

Also filed in the last 12 months, not counted as buying or selling: 45 sales to cover taxes, 15 option exercises, 11 stock grants, and 3 sales back to the company.

SEC filings

Recent issuer filings from EDGAR, 10 shown.

Filed Form Detail Links
10-Q
8-K 2.02,9.01
8-K 5.07
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
DEF 14A
DEFA14A
8-K 2.02,9.01
10-K

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf